Xencor

XNCR50

$21.20arrow_drop_up1.67%$0.35

XNCR50

$21.20

arrow_drop_up1.67%$0.35

Performance History

There's no data available for key stats

There's no data available for ratios/profitability stats

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Xencor (XNCR)

Xencor Inc (XNCR) is a biopharmaceutical company focused on discovering and developing innovative antibody-based therapeutics for the treatment of autoimmune diseases, cancer, and other conditions. The company utilizes its proprietary XmAb technology platform to create antibody therapeutics with enhanced properties, including improved potency, stability, and half-life.

Xencor has a strong pipeline of product candidates across multiple therapeutic areas. One of its lead product candidates is XmAb5871, a monoclonal antibody targeting CD19 and CD32b receptors, which is being evaluated for the treatment of autoimmune diseases such as systemic lupus erythematosus and IgG4-related disease. The company also has several other product candidates in preclinical and clinical development.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Dr. Bassil I. Dahiyat Ph.D.
Headquarters: Monrovia
Employees: 281
Exchange: NASDAQ

Keep an eye on Xencor

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Xencor 's (XNCR) price per share?

The current price per share for Xencor (XNCR) is $21.2. The stock has seen a price change of $0.35 recently, indicating a 1.68% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Xencor (XNCR)?

For Xencor (XNCR), the 52-week high is $26.84, which is 26.6% from the current price. The 52-week low is $15.31, the current price is 38.47% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Xencor (XNCR) a growth stock?

Xencor (XNCR) has shown an average price growth of 0.41% over the past three years. It has received a score of 25 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Xencor as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Xencor (XNCR) stock price performance year to date (YTD)?

As of the latest data, Xencor (XNCR) has a year-to-date price change of -5.82%. Over the past month, the stock has experienced a price change of 25.74%. Over the last three months, the change has been 9.45%. Over the past six months, the figure is -6.85%. Looking at a longer horizon, the five-year price change stands at -40.25%.

help

Is Xencor (XNCR) a profitable company?

Xencor (XNCR) has a net income of -$126.09M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 93.17% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -367.44% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $168.34M, with a revenue growth rate of 2.28%, providing insight into the company's sales performance and growth. The gross profit is $156.84M. Operating income is noted at -$138.64M. Furthermore, the EBITDA is -$158.38M.

help

What is the market capitalization of Xencor (XNCR)?

Xencor (XNCR) has a market capitalization of $1.46B. The average daily trading volume is 1.02M, indicating the stock's liquidity and investor engagement.